O
HRTX icon

OppenheimerFunds’s Heron Therapeutics HRTX Stock Holding History

OppenheimerFunds’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$12.6M Buy
515,908
+56,646
+12% +$1.48M 0.02% 639
2018
Q4 		$11.9M Buy
459,262
+86,470
+23% +$2.38M 0.02% 634
2018
Q3 		$11.8M Buy
+372,792
New +$13.9M 0.01% 695

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

OppenheimerFunds's HRTX Position: Q1 2019 in Review

OppenheimerFunds increased its Heron Therapeutics (HRTX) stake by 12% in Q1 2019, buying an estimated $1.48M and bringing the position to 515,908 shares worth $12.6M. The position accounts for 0.02% of the portfolio, ranked #639.

OppenheimerFunds first reported a position in HRTX in Q3 2018 and has held it in 3 quarters since. 198 funds tracked by Wall St. Rank hold HRTX as of Q1 2019.

  • OppenheimerFunds held 515,908 shares of Heron Therapeutics worth $12.6M as of Q1 2019.
  • OppenheimerFunds bought 56,646 Heron Therapeutics shares in Q1 2019, an estimated $1.48M.
  • Heron Therapeutics made up 0.02% of OppenheimerFunds's portfolio in Q1 2019, its #639 holding.
  • OppenheimerFunds first reported a position in Heron Therapeutics in Q3 2018 and has held it in 3 quarters since.
  • 198 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2019.

Based on OppenheimerFunds's 13F filing for Q1 2019, filed 13 May 2019.